Compare stocks
Market: US
REGNRegeneron Pharmaceuticals
Add stock
Ticker or company
Summary

REGN
Regeneron Pharmaceuticals
$952,40Down −0,32%
Year: Up +37%
67/100★★★★★★★★★Ratio would watch
Open stock pageTraffic light — 10 checks
| Check | REGN5 ✓ 2 — 2 ✕ |
|---|---|
| P/E vs its history | 20,5 |
| P/E vs industry | 20,5 |
| Forward P/E | 13,8 |
| Revenue growth, YoY | +18,6% |
| EPS growth, YoY | +8,3% |
| Net margin | 28,5% |
| Net debt / EBITDA | −1,4 |
| Free cash flow | $3,83 bn |
| Share count over a year | −1,5% |
| Cash runway | n/anot needed |
Metrics
Best WorstNo mark — in between
| Metric · better | REGNTTM | Industry medianTTM |
|---|---|---|
| P/E TTM ↓ | 20,5 | 42,1 |
| Forward P/E ↓ | 13,8 | 18,7 |
| PEG ↓ | 1,2 | 4,1 |
| P/S TTM ↓ | 5,8 | 6,6 |
| EV/EBITDA ↓ | 18,2 | 28,2 |
| P/FCF ↓ | 27,2 | 26,0 |
Price, %
- REGNn/a
Returns
Best WorstNo mark — in between
| Period | REGN |
|---|---|
| 1 year | n/a |
| 3 years | n/a |
| 5 years | n/a |
| All time | n/a |
“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.
Analysts and insiders
Best WorstNo mark — in between
| REGN | |
|---|---|
| Share of “buy” | 72% |
| Beat the forecast | 4 of 4 |
| Average “surprise” | +16,8% |
| Insiders over 12 months | sales $57,9 m |
Details are on each stock page.